Search

Author/Creator Patni, Rajiv

1. A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. (April 2022)

Authors:
Cohen, Jeffrey A; Cameron, Michelle H; Goldman, Myla D; Goodman, Andrew D; Miller, Aaron E; Rollins, Anne; Llorens, Lily; Patni, Rajiv; Elfont, Robert; Johnson, Reed
Journal:
Multiple sclerosis
Issue:
Volume 28:Number 5(2022)
Page Start:
817
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102. Issue 2 (23rd February 2018)

Authors:
Isaacson, Stuart H.; Fahn, Stanley; Pahwa, Rajesh; Tanner, Caroline M.; Espay, Alberto J.; Trenkwalder, Claudia; Adler, Charles H.; Patni, Rajiv; Johnson, Reed
Journal:
Movement disorders clinical practice
Issue:
Volume 5:Issue 2(2018)
Page Start:
183
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. (April 2019)

Authors:
Cohen, Jeffrey A; Hunter, Samuel F; Brown, Theodore R; Gudesblatt, Mark; Thrower, Ben W; Llorens, Lily; Souza-Prien, Cindy J; Ruby, April E; Chernoff, David N; Patni, Rajiv
Journal:
Multiple sclerosis
Issue:
Volume 25:Number 4(2019)
Page Start:
601
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗